Newsroom | 89964 results

北京--(BUSINESS WIRE)--(美国商业资讯)-- 中国领先的生物制药公司科兴控股生物技术有限公司（Sinovac Biotech Ltd.，以下简称“科兴生物控股”、“科兴”或“公司”）（纳斯达克代码：SVA）董事会今日发布公告，就特别股东大会（“特别会议”）经过及相关事宜以正视听： 特别股东大会已于2025年7月8日由科兴生物董事长李嘉强合法宣布延期，延期原因系安提瓜法院就维梧资本与尚珹资本（以下称“尚珹资本/Prime”）（合称“异议投资者”）通过无效私募配售（PIPE）所获股份有效性尚待裁决。此次延期已获选举独立监察人认可，该监察人系唯一有权宣布并认证特别股东大会结果的法定机构。 赛富投资所谓“特别股东大会继续召开”的虚假主张属于蓄意欺瞒，并且完全违反公司章程及安提瓜法律。特别股东大会合法休会且在线上会议终止后，赛富投资与异议投资者的代表律师随即在未公布的地点及时间自导自演了一场无效的冒牌特别股东大会。该团体既未提前通知合法股东参会，亦未联系特别会议唯一法定会议主席李嘉强博士，更无选举监察人监督此冒牌会议。现任董事会了解到，卢毓琳（Yuk Lam Lo）先生尽管出席...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units (“RSUs”) representing 267,269 shares of Quanterix common stock to twenty employees newly-hired in connection with the acquisition of Akoya Biosciences, Inc. The equity awards were granted pursuant to the Nasd...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 17 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 121,700 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as i...

BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”) today issued the following update to set the record straight regarding the Special Meeting of Shareholders (the “Special Meeting”): The Special Meeting was validly adjourned by SINOVAC Chairman Chiang Li on July 8, 2025, due to pending litigation in Antigua regarding the validity of the shares purportedly issued following an invalid private investment in public equity (“PIPE”) to...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the primary analysis of the Phase 2 RAMP 201 clinical trial was published online in the Journal of Clinical Oncology (JCO). The data reported in the publication showed that avutometinib plus defactinib demonstrated a confirmed overall response rate (ORR) of 31% in all patients with recurrent low-grade...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July of an aggregate of 12,385 restricted stock units (RSUs) of the company’s common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant dat...

SAN CARLOS, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Elegen, een wereldleider in DNA-productie van de volgende generatie, en Nutcracker Therapeutics, een wereldleider in RNA-ontwerp en -productie van de volgende generatie, hebben vandaag de lancering aangekondigd van een testprogramma om het eerste volledig synthetische, celvrije productieplatform voor RNA-gebaseerde gepersonaliseerde kankertherapieën (PCT's) in de industrie te demonstreren. De test markeert een nieuwe stap in de richting...

SAN CARLOS, Californie et EMERYVILLE, Californie--(BUSINESS WIRE)--Elegen, le chef de file mondial de la fabrication d’ADN de nouvelle génération, et Nutcracker Therapeutics, leader mondial de la conception et de la fabrication d’ARN de nouvelle génération, annoncent aujourd’hui le lancement d’un programme pilote visant à démontrer la première plateforme de fabrication entièrement synthétique et sans cellule de l’industrie pour les thérapies personnalisées contre le cancer à base d’ARN. Le proj...

SAN CARLOS, Calif. e EMERYVILLE, Calif.--(BUSINESS WIRE)--Elegen, un leader globale nella produzione di DNA di nuova generazione, e Nutcracker Therapeutics, un leader globale nella progettazione e produzione di RNA di nuova generazione, oggi hanno annunciato il lancio di un programma pilota per dimostrare la prima piattaforma nel settore per la produzione interamente sintetica e priva di cellule di terapie oncologiche personalizzate (PCT) a base di RNA. Il programma pilota segna un passo avanti...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today that the Company signed a financial agreement with the European Investmen...